Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in combination with ...

SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine ...

(NASADAQ: AGEN), a leader in immuno-oncology, recently announced it too will share five presentations at ASCO GI's symposium ...

(NASADAQ: AGEN), a leader in immuno-oncology, recently announced it too will share five presentations at ASCO GI's symposium featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ...

Investors and interested parties are advised that the forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from those ...

This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® ...

We will be working diligently to move this project forward”, said Dr. Faming Zhang, chairman of Hanx Biopharmaceuticals. “HX044 is a next generation CTLA-4 bispecific antibody fully developed in-house ...

We will be working diligently to move this project forward”, said Dr. Faming Zhang, Chairman of Hanx Biopharmaceuticals. “HX044 is a next generation CTLA-4 bispecific antibody fully developed in-house ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria. A novel class of antibodies that binds to ...